Preferentially expressed antigen in melanoma (PRAME) ALYVDSLFFL peptide presented by HLA-A*02:01 (PRAME ALYVDSLFFL/HLA-A*02:01)

The Preferentially expressed antigen in melanoma (PRAME) ALYVDSLFFL peptide presented by HLA-A*02:01 is a specific peptide-major histocompatibility complex (pMHC) target utilized in cancer immunotherapy. PRAME is a cancer-testis antigen (CTA) that is typically expressed in the testis but is aberrantly overexpressed in a wide variety of solid tumors and hematologic malignancies, including melanoma, sarcoma, and acute myeloid leukemia [1, 2]. The ALYVDSLFFL epitope (amino acids 300-309) is a highly immunogenic peptide that is processed and displayed on the cell surface by the HLA-A*02:01 molecule [3]. This pMHC complex serves as a docking site for engineered T-cell receptors (TCRs) in therapies such as TCR-T cells and TCR-bispecific engagers [4]. By targeting this specific complex, these therapies aim to induce selective T-cell mediated destruction of tumor cells while minimizing damage to healthy tissues, which generally lack PRAME expression [5]. Clinical candidates like IMA203 and IMA402 are currently being evaluated for their ability to treat HLA-A*02:01-positive patients whose tumors express the PRAME antigen [4, 6].

Other names

PRAME-A2PRAME 300-309 HLA-A*02:01PRAME pMHC complexPRAME-001

T-cell receptor (TCR) binding and activation of T-cell mediated cytotoxicity against cells presenting the PRAME ALYVDSLFFL epitope [4, 5].